Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Heart Failure 1

Interventions

Cisplatin 3193 Cyclophosphamide 3187 Carboplatin 2968 Radiotherapy 2784 Paclitaxel 2716 Gemcitabine 2569 pembrolizumab 2378 Bevacizumab 2206 Docetaxel 2196 Fluorouracil 1848 Capecitabine 1828 Oxaliplatin 1738 Dexamethasone 1604 Nivolumab 1580 Doxorubicin 1501 Rituximab 1487 Magnetic Resonance Spectroscopy 1382 Etoposide 1345 Irinotecan 1245 Leucovorin 1222 Drug Therapy 1202 Cytarabine 1130 Pemetrexed 1074 fludarabine 1056 Specimen Handling 1009 Vincristine 964 Cetuximab 943 Prednisone 940 Trastuzumab 940 Lenalidomide 937

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Simendan × Clear all

NCT03557255 2018-06-14

Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries

National Cancer Institute, Egypt

Phase 2 Completed

Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon ⚡